Pall Technology Helps Alleviate Critical Blood Shortages



    EAST HILLS, N.Y., September 19 /CNW/ - Each year in the U.S. millions of
blood donors see a critical part of their donation literally go down the
drain. Of the 14.4 million units of whole blood collected annually, a majority
(about two-thirds) of the four million whole blood-derived platelet
concentrates are discarded. Many blood banks are replacing this valuable
resource with much more expensive single donor (apheresis) platelets. Yet
there is no medical requirement or clear need to do so. Today Pall Corporation
(NYSE:   PLL) is working closely with leading blood banks to change this
outdated practice. They are adopting Pall's Acrodose(TM) PL System to
efficiently increase the availability of safe platelets for transfusion by
making use of the abundant resource of whole blood-derived platelets.

    The margin between supply of blood products and demand is smaller than it
has ever been. With more stringent screening procedures and donor restrictions
along with an aging population, this margin is forecasted to decrease each
year. As the donor pool continues to shrink, the risk of blood shortages to
our nation increases. Since the U.S. blood supply is dependent on the
generosity of volunteer donors, experts urge using their valuable contribution
more wisely. This means applying technology that allows blood banks to not
waste important blood resources. Several patients can benefit from a single
unit of donated whole blood with up to four blood components derived from each
unit. The Acrodose PL System provides a new approach to efficiently use whole
blood to make safe platelets more readily available.

    The resulting Acrodose(SM) Platelet is an innovative product that can
provide significant advantages over single-donor platelets and other whole
blood-derived platelet products. Acrodose Platelets are leukocyte (white blood
cell) reduced, matched for blood type and tested for bacteria using a
sensitive culture-based system, the same type of state-of- the- art systems
that are used to test single-donor platelets. This transfusion-ready,
therapeutic dose of platelets is clinically equivalent in terms of platelet
count and quality to those derived from apheresis, but at a lower cost.

    "The use of culture testing has added a new standard of care to whole
blood-derived platelets making their safety from bacterial contamination, the
leading infectious cause of morbidity and mortality associated with platelets,
comparable to apheresis derived platelets," says Joseph Sweeney, MD, Director
of Transfusion Medicine and Professor of Pathology and Laboratory Medicine at
Brown University, Providence, Rhode Island. "Blood centers that incorporate
the Acrodose PL System into their process no longer have to trade off between
platelet safety and availability."

    Platelets, used to aid blood clotting, are in high demand for people with
leukemia, blood disorders or cancer; recipients of bone marrow or organ
transplants and accident, burn and trauma victims. Platelets are a valuable
resource that must be transfused within five days of collection before
expiring. Reliance on single-donor platelets which are expensive and
time-consuming to collect may lead to blood shortages and cause strains on
hospitals to meet patient needs.

    Five or Seven Day Platelet

    Shortages in platelet supply have led some blood centers to consider use
of platelets stored longer than five days to help improve platelet
availability. Studies have shown that platelets at greatest risk for
transfusion-associated bacterial sepsis have the longest storage age.
According to a report in the August 2007 issue of Transfusion, there is also a
strong correlation between storage age with the severity of the resulting
sepsis. (Sepsis is a severe infection of the blood and tissues which can lead
to shock, organ failure and death.)

    Extending platelet storage from 5 to 7 days can result in an increase in
transfusion-associated sepsis and also require additional testing, increasing
expense, time and handling costs. With the Acrodose PL System, blood centers
and hospitals will be able to efficiently reduce the problem of platelet
availability without having to consider using 7-day storage platelets.

    About Pall Corporation

    Pall Corporation is the global leader in the rapidly growing field of
filtration, separation and purification. Pall is organized into two
businesses: Life Sciences and Industrial. These businesses provide
leading-edge products to meet the demanding needs of customers in
biotechnology, pharmaceutical, transfusion medicine, energy, electronics,
municipal and industrial water purification, aerospace, transportation and
broad industrial markets. Total revenues for fiscal year 2006 were $2.0
billion. The Company's headquarters are in East Hills, New York, with
extensive operations throughout the world. For more information visit Pall at
http://www.pall.com.

    Editor's Notes:

    --  Photos are available on http://www.pall.com/corporate_43812.asp

    --  Additional information about Acrodose(TM) PL System can be found at
www.pall.com/acrodose

    MULTIMEDIA AVAILABLE:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5495953




For further information:

For further information: Marcia Katz Pall Corporation 516 801-9851
Marcia_Katz@pall.com

Organization Profile

PALL CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890